Busque Philippe 4

What Happened Philippe Busque, SVP, Global Sales and Services at Cytek Biosciences (CTKB), had restricted stock units (RSUs) and derivative awards vest/convert on March 10, 2026. The filing shows grants/awards of 70,665 and 133,226 RSUs (total 203,891 RSUs, recorded as acquired at $0) and the conversion/exercise of three derivative lots totaling 9,828 shares (2,049 + 2,946 + 4,833). To satisfy tax withholding arising from vesting, 635 + 912 + 1,496 = 3,043 shares were withheld and surrendered to the issuer at $4.23 per share, totaling $12,872. There is no indication of an open-market sale — the withheld shares were used to cover taxes.

Key Details

• Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (within the normal 2‑business‑day window).
• Awards/Acquisitions: 70,665 RSUs and 133,226 RSUs (acquired at $0; RSUs are contingent rights to one share each — see footnote F1).
• Exercises/Conversions: 2,049; 2,946; and 4,833 derivative shares converted/exercised (total 9,828).
• Tax withholding (code F): 635; 912; and 1,496 shares withheld at $4.23/share, totaling $12,872 (footnote F2).
• Shares owned after the transactions: Not specified in the provided excerpt of the filing.
• Notable footnotes: RSUs convert to one share each (F1); withheld shares were surrendered to satisfy tax liabilities on the RSU vesting (F2); various footnotes (F3–F7) describe multi‑year vesting schedules for the options and RSU awards.
• Transaction codes: A = Award/Grant; M = Option exercise/conversion; F = Payment of exercise price or tax withholding.

Context

• This filing shows awards vesting and derivative conversions with share withholding for taxes — not an open‑market sale or purchase. Withholding to cover taxes is a routine administrative step and does not necessarily signal insider sentiment.
• For clarity: “M” entries indicate exercise/conversion of derivatives (options or vested RSUs); the withheld shares (F) are the issuer withholding shares to cover tax obligations rather than a market sale.